JP2015522561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522561A5 JP2015522561A5 JP2015516198A JP2015516198A JP2015522561A5 JP 2015522561 A5 JP2015522561 A5 JP 2015522561A5 JP 2015516198 A JP2015516198 A JP 2015516198A JP 2015516198 A JP2015516198 A JP 2015516198A JP 2015522561 A5 JP2015522561 A5 JP 2015522561A5
- Authority
- JP
- Japan
- Prior art keywords
- galacto
- composition
- kda
- rhamnogalacturonate
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 12
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-Galacturonic acid Chemical group OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 claims 9
- UNSKAUSCLTVFGO-KCDKBNATSA-N methyl (2S,3R,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoate Chemical compound COC(=O)[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O UNSKAUSCLTVFGO-KCDKBNATSA-N 0.000 claims 6
- 210000002540 Macrophages Anatomy 0.000 claims 5
- 210000001616 Monocytes Anatomy 0.000 claims 5
- PNNNRSAQSRJVSB-BXKVDMCESA-N Rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 claims 5
- 238000004166 bioassay Methods 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 210000004185 Liver Anatomy 0.000 claims 4
- 101700049309 NOS2 Proteins 0.000 claims 4
- 102100002496 NOS2 Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 210000001130 Astrocytes Anatomy 0.000 claims 3
- 206010003816 Autoimmune disease Diseases 0.000 claims 3
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 3
- 102000007563 Galectins Human genes 0.000 claims 3
- 108010046569 Galectins Proteins 0.000 claims 3
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 3
- 230000001684 chronic Effects 0.000 claims 3
- 229920000140 heteropolymer Polymers 0.000 claims 3
- 200000000018 inflammatory disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 230000003078 antioxidant Effects 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 239000003833 bile salt Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N (2S,3S,4R,5S)-2,3,4,5-tetrahydroxyhexanal Chemical group C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 claims 1
- NIGNBCLEMMGDQP-UHFFFAOYSA-N 1-benzothiepine Chemical class S1C=CC=CC2=CC=CC=C12 NIGNBCLEMMGDQP-UHFFFAOYSA-N 0.000 claims 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 claims 1
- 101710028063 APCS Proteins 0.000 claims 1
- 102100003659 APCS Human genes 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- 229960001091 Chenodeoxycholic Acid Drugs 0.000 claims 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N Chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims 1
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims 1
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims 1
- 229940099500 Cystamine Drugs 0.000 claims 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N Cysteamine Chemical group NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 1
- 229940119025 Cysteamine Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 210000004443 Dendritic Cells Anatomy 0.000 claims 1
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N HMG-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 229940067606 Lecithin Drugs 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 229960003151 Mercaptamine Drugs 0.000 claims 1
- 108020005203 Oxidases Proteins 0.000 claims 1
- 102100004022 PTPRU Human genes 0.000 claims 1
- 101700071602 PTPRU Proteins 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 229940046001 Vitamin B Complex Drugs 0.000 claims 1
- 229940046009 Vitamin E Drugs 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 229960003487 Xylose Drugs 0.000 claims 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical group OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 claims 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 150000001747 carotenoids Chemical class 0.000 claims 1
- 238000003570 cell viability assay Methods 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 229950001904 chenodiol Drugs 0.000 claims 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 claims 1
- 231100000406 dermatitis Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000009650 gentamicin protection assay Methods 0.000 claims 1
- 229960003776 glatiramer acetate Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 150000002515 isoflavone derivatives Chemical class 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
- 229940121649 protein inhibitors Drugs 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 239000002469 receptor inverse agonist Substances 0.000 claims 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000009594 systemic scleroderma Diseases 0.000 claims 1
- 235000019529 tetraterpenoid Nutrition 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 150000003712 vitamin E derivatives Chemical class 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
Claims (16)
- 自己免疫性疾患、慢性炎症性疾患、神経変性疾患または心血管疾患を含む高iNOSと関連する疾患の処置のための医薬組成物であって、該組成物は、許容される医薬担体中にガラクト−ラムノガラクツロネートを含む非経腸または経腸投与用組成物であり、該ガラクト−ラムノガラクツロネートが、α−1,2−結合ラムノースおよびα−1,4−結合GalA残基の交互オリゴマーである分岐へテロポリマーを結合する、1,4−結合ガラクツロン酸(GalA)およびメチルガラクツロネート(MeGalA)残基の主鎖を含み、該ラムノース残基が、1,4−β−D−ガラクトース残基、1,5−α−L−アラビノース残基またはそれらの組み合わせのオリゴマーである主な分岐を有し、そして、該組成物が、疾患の影響を受ける組織におけるiNOSの発現を少なくとも10%減少させる、医薬組成物。
- 自己免疫疾患、慢性炎症性疾患、神経変性疾患または心血管疾患を含む高iNOSと関連する疾患の処置のための医薬組成物の製造におけるガラクト−ラムノガラクツロネート化合物の使用であって、該ガラクト−ラムノガラクツロネートが、α−1,2−結合ラムノースおよびα−1,4−結合GalA残基の交互オリゴマーである分岐へテロポリマーを結合する、1,4−結合ガラクツロン酸(GalA)およびメチルガラクツロネート(MeGalA)残基の主鎖を含み、該ラムノース残基が、1,4−β−D−ガラクトース残基、1,5−α−L−アラビノース残基、またはそれらの組み合わせのオリゴマーである主な分岐を有する、使用。
- 自己免疫疾患、慢性炎症性疾患、神経変性疾患または心血管疾患を含む高iNOSと関連する疾患の処置のための、ガラクト−ラムノガラクツロネートおよび治療剤を含む混合物であって、該ガラクト−ラムノガラクツロネートが、α−1,2−結合ラムノースおよびα−1,4−結合GalA残基の交互オリゴマーである分岐へテロポリマーを結合する、1,4−結合ガラクツロン酸(GalA)およびメチルガラクツロネート(MeGalA)残基の主鎖を含み、該ラムノース残基が、1,4−β−D−ガラクトース残基、1,5−α−L−アラビノース残基、またはそれらの組み合わせのオリゴマーである主な分岐を有する、混合物。
- 1,4−β−D−ガラクトースおよび1,5−α−L−アラビノース残基が、2:1ないし3:1の比で存在する、請求項1に記載の組成物、請求項2に記載の使用または請求項3に記載の混合物。
- 1,4−β−D−ガラクトース残基、1,5−α−L−アラビノース残基またはそれらの組み合わせが、炭水化物の総モルの少なくとも10モル%の量で存在し、要すれば、該ガラクトアラビノ−ラムノガラクツロネートが、およそ1:1ないし3:1の範囲の比の1,4−β−D−Galおよび1,5−α−L−Ara残基を炭水化物の総モルの10%を超え得るモル%で含む、請求項1ないし4のいずれか一項に記載の組成物、使用または混合物。
- ガラクト−ラムノガラクツロネートが、キシロース、グルコース、フコース残基またはそれらの組み合わせをさらに含む、請求項1ないし5のいずれか一項に記載の組成物、使用または混合物。
- ガラクト−ラムノガラクツロネートが、5kDa〜55kDa、2kDa〜80kDa、20kDa〜70kDa、2kDa〜65kDa、45kDa〜65kDaまたは2kDa〜20kDaの範囲の平均分子量を有する、請求項1ないし6のいずれか一項に記載の組成物、使用または混合物。
- ガラクト−ラムノガラクツロナン化合物を、エンドトキシンによりストレスを受けた単球またはマクロファージを処理するアッセイにおいて使用するとき、該アッセイにより、活性化単球またはマクロファージからのTNFαサイトカインが低下する、請求項1および4ないし7のいずれか一項に記載の組成物。
- ガラクト−ラムノガラクツロナン化合物が、活性化単球または活性化マクロファージによるTNFαの分泌を少なくとも25%減少させることができる、請求項8に記載の組成物。
- ガラクト−ラムノガラクツロナン化合物を、細胞生存アッセイにおいて、LX2不死化ヒト肝臓星状細胞の処理に用いたとき、該処理により、ガラクト−ラムノガラクツロナン化合物の投与後に活性化した肝臓星状細胞の生存率を実質的に低下させない、請求項1および4ないし9のいずれか一項に記載の組成物。
- ガラクト−ラムノガラクツロネートを投与する工程において、該化合物を有効量の治療剤と共投与する、請求項1および4ないし10のいずれか一項に記載の組成物。
- 該治療剤が、システアミンもしくはその薬学的に許容される塩、シスタミンもしくはその薬学的に許容される塩、抗酸化化合物、レシチン、ビタミンB複合体、胆汁塩製剤、カンナビノイド−1(CB1)受容体アンタゴニスト、カンナビノイド−1(CB1)受容体インバースアゴニスト、ペルオキシソーム増殖剤活性化受容体活性調節剤、ベンゾチアゼピンもしくはベンゾチエピン化合物、タンパク質チロシンホスファターゼPTPRUを阻害するRNAアンチセンス構築物、ヘテロ原子結合置換ピペリジンおよびその誘導体、アザシクロペンタン誘導体、アディポネクチンの分泌促進または誘導活性を有するアシルアミド化合物、第四級アンモニウム化合物、グラチラマーアセテート、ペントラキシンタンパク質、HMG−CoAレダクターゼ阻害剤、N−アセチルシステイン、イソフラボン化合物、マクロライド抗生物質、ガレクチン阻害剤、またはそれらの組み合わせの1つである、請求項3に記載の混合物または請求項11に記載の組成物。
- i)抗酸化化合物が、水溶性ビタミンE製剤、カロテノイド混合物、セレン、またはそれらの組み合わせを含み、ii)胆汁塩製剤が、ウルソデオキシコール酸、天然に存在する胆汁酸もしくは胆汁酸塩のケノデオキシコール酸、合成胆汁酸もしくは胆汁酸塩のケノデオキシコール酸、またはそれらの組み合わせを含み、iii)ペントラキシンタンパク質が、組換えペントラキシン−2であり、iV)HMG−CoAレダクターゼ阻害剤が、アトルバスタチン、シンバスタチンまたはそれらの組み合わせを含み、またはV)ガレクチン阻害剤が、低分子有機ガレクチン阻害剤、モノクローナル抗体、RNA阻害剤、低分子結合ペプチド、タンパク質阻害剤、またはそれらの組み合わせを含む、請求項12に記載の組成物。
- 治療剤が、抗リシルオキシダーゼ抗体、または結合組織増殖因子に対する抗体である、請求項3に記載の混合物または請求項11に記載の組成物。
- i)ガラクト−ラムノガラクツロナン化合物を、エンドトキシンによりストレスを受けた単球またはマクロファージを処理するアッセイにおいて使用するとき、該アッセイにより、活性化単球またはマクロファージからのTNFαサイトカインが少なくとも25%低下し、および/または
ii)ガラクト−ラムノガラクツロナン化合物を、細胞生存アッセイにおいて、LX2不死化ヒト肝臓星状細胞の処理に用いたとき、該アッセイにより、該化合物の投与後に活性化した肝臓星状細胞の生存率を実質的に低下させない、
請求項3から5、7および12のいずれか一項に記載の混合物。 - 該疾患が、乾癬、皮膚および全身性エリテマトーデス、全身性硬化症ならびに皮膚炎のいずれかである、請求項1に記載の組成物、請求項2に記載の使用または請求項3に記載の混合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261656288P | 2012-06-06 | 2012-06-06 | |
US61/656,288 | 2012-06-06 | ||
PCT/US2013/044478 WO2013184892A1 (en) | 2012-06-06 | 2013-06-06 | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015522561A JP2015522561A (ja) | 2015-08-06 |
JP2015522561A5 true JP2015522561A5 (ja) | 2016-07-14 |
JP6517141B2 JP6517141B2 (ja) | 2019-05-22 |
Family
ID=49712624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015516198A Active JP6517141B2 (ja) | 2012-06-06 | 2013-06-06 | 高誘導型一酸化窒素合成酵素と関連する疾患を処置するためのガラクト−ラムノガラクツロネート組成物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9763974B2 (ja) |
EP (1) | EP2858651B1 (ja) |
JP (1) | JP6517141B2 (ja) |
KR (1) | KR102071739B1 (ja) |
CN (1) | CN104619329B (ja) |
AU (1) | AU2013271585B2 (ja) |
BR (1) | BR112014030534A2 (ja) |
CA (1) | CA2875979C (ja) |
ES (1) | ES2848538T3 (ja) |
IL (1) | IL236067B (ja) |
MX (1) | MX2014014979A (ja) |
WO (1) | WO2013184892A1 (ja) |
ZA (1) | ZA201409195B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008011216A2 (en) * | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
BR112014015940B1 (pt) | 2011-12-28 | 2022-08-09 | Galectin Therapeutics, Inc | Polissacarídeo de grau farmacêutico, composição, e seus usos |
US9763974B2 (en) | 2012-06-06 | 2017-09-19 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
EP2900061B1 (en) | 2012-09-17 | 2020-01-22 | Galectin Therapeutics Inc. | Method for enhancing specific immunotherapies in cancer treatment |
WO2014130648A1 (en) | 2013-02-20 | 2014-08-28 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
US20170232035A1 (en) * | 2014-08-18 | 2017-08-17 | Pharmagenesis, Inc. | Polygalacturonan Rhamnogalacturonan1 (PGRG1) Composition |
JP2021529163A (ja) | 2018-06-29 | 2021-10-28 | グリコス バイオメディカル オーワイ | コンジュゲート |
WO2021064729A1 (en) * | 2019-10-02 | 2021-04-08 | Patchor Ltd. | Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof |
US20230038373A1 (en) | 2019-12-18 | 2023-02-09 | Glykos Biomedical Oy | Stabile conjugate |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897A (en) | 1851-01-14 | Improvement in raising carriage-tops | ||
US583A (en) | 1838-01-27 | Hviprovement in horizontal windmills | ||
US2132577A (en) | 1934-08-28 | 1938-10-11 | Gen Foods Corp | Method of preparing pectin |
US2444266A (en) | 1944-03-31 | 1948-06-29 | Us Agriculture | Pectic materials and method of preparing same |
US2503258A (en) | 1948-01-23 | 1950-04-11 | Us Agriculture | Neutralization of pectinic acids with sodium bicarbonate |
US4016351A (en) | 1976-02-04 | 1977-04-05 | Eschinasi Emile H | Pectic substances with varying methoxyl content and process therefor |
US4268533A (en) | 1979-11-21 | 1981-05-19 | General Foods Corporation | Quick-set low methoxyl pectin composition |
JPS61502124A (ja) | 1984-05-09 | 1986-09-25 | ジ オ−ストラリアン ナシヨナル ユニヴア−シテイ− | 免疫応答の調節方法 |
US4686106A (en) | 1986-06-16 | 1987-08-11 | General Foods Corporation | Pectin food product |
US5071970A (en) | 1988-11-23 | 1991-12-10 | University Of Florida | Process for producing pectin with a high-to-medium methoxyl content from beet pulp |
DE4011285A1 (de) | 1990-04-06 | 1991-10-10 | Steigerwald Arzneimittelwerk | Arzneimittel zur behandlung von hyperlipidaemie und/oder atherosklerose |
US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
US7491708B1 (en) | 1993-03-01 | 2009-02-17 | David Platt | Modified pectin |
US5498702A (en) | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
US5834442A (en) | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
US6297229B1 (en) | 1994-11-14 | 2001-10-02 | Mayo Foundation For Medical Education And Research | Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis |
US5760010A (en) | 1995-01-01 | 1998-06-02 | Klein; Ira | Method of treating liver disorders with a macrolide antibiotic |
US5681923A (en) | 1995-10-06 | 1997-10-28 | Platt; David | Tumor derived carbohydrate binding protein |
US6632797B2 (en) | 1996-06-24 | 2003-10-14 | Matti Siren | Method of treating angiogenesis |
JPH10117800A (ja) * | 1996-08-30 | 1998-05-12 | Akita Pref Gov | 単糖、オリゴ糖または可溶化多糖の製造法 |
US5929051A (en) * | 1998-05-13 | 1999-07-27 | Carrington Laboratories, Inc. | Aloe pectins |
US7022683B1 (en) * | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
US6180139B1 (en) | 1998-12-04 | 2001-01-30 | Viva America Marketing, Inc. | Composition and method for treating nonalcoholic steatohepatitis |
US6500807B1 (en) | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
AU4055000A (en) | 1999-04-13 | 2000-11-14 | Daniel K. Hsu | Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma |
AU777254B2 (en) | 1999-04-20 | 2004-10-07 | Board Of Trustees Of Southern Illinois University, The | Methods of treating clinical diseases with isoflavones |
IT1316986B1 (it) | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
CN1142272C (zh) | 2000-02-02 | 2004-03-17 | 中国人民解放军军事医学科学院百环生物医学研究中心 | 携带人肝细胞生长因子基因的重组腺病毒的用途 |
WO2001056547A2 (en) | 2000-02-04 | 2001-08-09 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
US6596762B2 (en) | 2001-05-17 | 2003-07-22 | The Regents Of The University Of Colorado | Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis |
US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
US6680306B2 (en) | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
US20030004132A1 (en) | 2001-06-22 | 2003-01-02 | Yan Chang | Method and material for treating immune diseases |
US20040241138A1 (en) | 2001-07-20 | 2004-12-02 | Hsu Henry H. | Methods of treating liver fibrosis |
US20040121981A1 (en) | 2001-11-21 | 2004-06-24 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
US6890906B2 (en) | 2001-11-21 | 2005-05-10 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
JP2004107295A (ja) | 2002-09-20 | 2004-04-08 | National Agriculture & Bio-Oriented Research Organization | ヒスタミン遊離抑制剤 |
JP2006522163A (ja) | 2003-04-07 | 2006-09-28 | グリコジェネシス, インク. | ガレクチンアンタゴニストの組成物と使用 |
US20040223971A1 (en) | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
WO2004096998A2 (en) | 2003-04-29 | 2004-11-11 | Vanderbilt University | Nanoparticular tumor targeting and therapy |
US20050053664A1 (en) | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
US7078064B2 (en) | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
CN1930137B (zh) | 2004-02-27 | 2011-07-20 | 旭化成制药株式会社 | 苯并硫氮杂卓和苯并虑平化合物 |
CA2582428A1 (en) | 2004-03-26 | 2005-10-13 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
JP2008105945A (ja) | 2005-02-07 | 2008-05-08 | Ajinomoto Co Inc | アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物 |
EP1924294A4 (en) | 2005-05-24 | 2010-11-03 | Isis Pharmaceuticals Inc | COMPOSITIONS AND USES FOR MODULATING EXPRESSION OF PTPRU |
MX2007014501A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos novedosos que contienen acido fosfinico. |
US7635705B2 (en) | 2005-06-20 | 2009-12-22 | Schering Corporation | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists |
US7897591B2 (en) | 2005-07-28 | 2011-03-01 | Children's Medical Center Corporation | Method of treating fatty liver disease |
US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
WO2008011216A2 (en) * | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
JP5105297B2 (ja) | 2006-05-25 | 2012-12-26 | 味の素株式会社 | Ppar活性調節剤 |
CA2654098A1 (en) | 2006-06-13 | 2007-12-21 | Merck Frosst Canada Ltd. | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
ES2417179T3 (es) | 2007-11-30 | 2013-08-06 | The Regents Of The University Of California | Métodos para tratar la esteatohepatitis no alcohólica (EHNA) mediante productos basados en cisteamina |
EP2260305A1 (en) | 2008-03-27 | 2010-12-15 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Methods and kits for determining the occurrence of a liver disease in a subject |
KR101074158B1 (ko) | 2008-04-07 | 2011-10-17 | 재단법인 한국원자력의학원 | 간 보호 또는 간 질환의 예방 및 치료용 인삼다당체 조성물 |
WO2009151116A1 (ja) | 2008-06-13 | 2009-12-17 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防/改善・治療薬 |
JP2010229099A (ja) | 2009-03-27 | 2010-10-14 | Mochida Pharmaceut Co Ltd | 脂質異常症の改善または治療薬 |
WO2013010134A2 (en) | 2011-07-14 | 2013-01-17 | Celula, Inc. | Systems, apparatus and methods for biochemical analysis |
US8658787B2 (en) * | 2011-09-16 | 2014-02-25 | Galectin Therapeutics Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
BR112014015940B1 (pt) * | 2011-12-28 | 2022-08-09 | Galectin Therapeutics, Inc | Polissacarídeo de grau farmacêutico, composição, e seus usos |
US9763974B2 (en) | 2012-06-06 | 2017-09-19 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
EP2900061B1 (en) * | 2012-09-17 | 2020-01-22 | Galectin Therapeutics Inc. | Method for enhancing specific immunotherapies in cancer treatment |
-
2013
- 2013-06-06 US US14/405,280 patent/US9763974B2/en active Active
- 2013-06-06 WO PCT/US2013/044478 patent/WO2013184892A1/en active Application Filing
- 2013-06-06 MX MX2014014979A patent/MX2014014979A/es active IP Right Grant
- 2013-06-06 CN CN201380041782.7A patent/CN104619329B/zh active Active
- 2013-06-06 ES ES13800900T patent/ES2848538T3/es active Active
- 2013-06-06 BR BR112014030534A patent/BR112014030534A2/pt not_active Application Discontinuation
- 2013-06-06 KR KR1020147035737A patent/KR102071739B1/ko active IP Right Grant
- 2013-06-06 EP EP13800900.6A patent/EP2858651B1/en active Active
- 2013-06-06 CA CA2875979A patent/CA2875979C/en active Active
- 2013-06-06 AU AU2013271585A patent/AU2013271585B2/en active Active
- 2013-06-06 JP JP2015516198A patent/JP6517141B2/ja active Active
-
2014
- 2014-12-04 IL IL236067A patent/IL236067B/en active IP Right Grant
- 2014-12-12 ZA ZA2014/09195A patent/ZA201409195B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015522561A5 (ja) | ||
JP2014526513A5 (ja) | ||
HRP20210034T1 (hr) | Farmaceutski pripravci koji sadrže meloksikam i rizatriptan | |
Kim et al. | Injectable hyaluronic acid–tyramine hydrogels for the treatment of rheumatoid arthritis | |
Tu et al. | Chitosan nanoparticles reduce LPS-induced inflammatory reaction via inhibition of NF-κB pathway in Caco-2 cells | |
EP2872181B1 (en) | Compositions containing hc-ha/ptx3 complexes and methods of use thereof | |
ES2848538T3 (es) | Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible | |
EP2178565A1 (fr) | COMPLEXES ENTRE UN POLYMÈRE AMPHIPHILE ET UNE PROTÉINE OSTÉOGÉNIQUE APPARTENANT À LA FAMILLE DES BMPs | |
FR2891149A1 (fr) | Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes. | |
Choukaife et al. | Current advances in chitosan nanoparticles based oral drug delivery for colorectal cancer treatment | |
JP2012515170A5 (ja) | ||
JP2015503658A5 (ja) | ||
Lo et al. | In situ chemically crosslinked injectable hydrogels for the subcutaneous delivery of trastuzumab to treat breast cancer | |
WO2011015634A3 (en) | Controlled release formulations of lipocalin muteins | |
JP2007504273A5 (ja) | ||
TW200824719A (en) | Stable liquid compositions for treating stomatitis comprising epidermal growth factor | |
WO2019010490A1 (en) | BIOCONJUGATES WITH CHEMICALLY MODIFIED SKELETONS | |
Shen et al. | Scavenging of reactive oxygen species can adjust the differentiation of tendon stem cells and progenitor cells and prevent ectopic calcification in tendinopathy | |
HRP20150363T1 (hr) | Kompozicije koje sadrže core-1 pozitivni mikroorganizam i njihova primjena za lijeäśenje ili profilaksu tumora | |
Yao et al. | Nano-particle engineered atorvastatin delivery to support mesenchymal stem cell survival in infarcted myocardium | |
US20190160183A1 (en) | Compositions comprising a polysaccharide matrix for the controlled release of active ingredients | |
Gumus et al. | mTOR pathway and its role in rheumatologic diseases/mTOR yolagi ve romatolojik hastaliklardaki rolu. | |
Dubashynskaya et al. | Biopolymer Drug Delivery Systems for Oromucosal Application: Recent Trends in Pharmaceutical R & D | |
JP2022534278A (ja) | 血液脳関門(bbb)の保護及び修復のための組成物 | |
CO2021009028A2 (es) | Composiciones para uñas con propiedades antifúngicas |